In both MS and RA, TNF-α and IL-6 were found to be elevated and associated with pathogenesis, leading to the approval of anti-TNF-α and IL-6 receptor antagonists for the treatment of RA [1, 4–7]. This evidence concerns the gene TNF and myeloid sarcoma.